Table 1 Relationship between the clinical features of glioma and ABCC8 mRNA expression in CGGA. *According to the median age of 42 years, the patients were divided into two groups. LGG: lower grade glioma (WHO II and WHO III). GBM: glioblastoma.

Parameter	Variables	N	ABCC8 mRNA expression				χ²	P value
Parameter	Variables	N	Low	%	High	%	χ²	P value
Age*	< 42	303	148	48.80	155	51.20	0.301	0.584
Age*	≥ 42	353	180	51.00	173	49.00
Gender	Female	282	137	48.60	145	51.40	0.398	0.528
Gender	Male	374	191	51.10	183	48.90
Histopathology	Oligodendroglioma	144	28	19.40	116	80.60	115.567	0.000
	Astrocytoma	274	122	44.50	152	55.50
	Glioblastoma	238	178	74.80	60	25.20
WHO grade	II	176	49	27.80	127	72.20	99.684	0.000
	III	242	101	41.70	141	58.30
	IV	238	178	74.80	60	25.20
IDH mutation	Wildtype	277	197	71.10	80	28.90	67.345	0.000
	Mutant	331	125	37.80	206	62.20
	NA	48
1p/19q codel	Non-codel	461	251	54.40	210	45.60	60.950	0.000
	Codel	141	24	17.00	117	83.00
	NA	54
Radiotherapy	No	134	50	37.30	84	62.70	10.023	0.002
	Yes	495	261	52.70	234	47.30
	NA	27
Chemotherapy	No	157	60	38.20	97	61.80	11.314	0.001
	Yes	471	253	53.70	218	46.30
	NA	28
WHO grade (2016)	IDH Mutant, 1p/19q Codel (LGG)	114	21	18.40	93	81.60	114.393	0.000
	IDH Mutant, 1p/19q Non-codel (LGG)	171	75	43.9	96	56.1
	IDH Wildtype (LGG)	95	52	54.7	43	45.3
	IDH Mutant (GBM)	46	29	63.0	17	37.0
	IDH wildtype (GBM)	182	145	79.7	37	20.3
	NA	48

Quick links

Search